Respimat Technology

This unique partnership sets Kenox apart, allowing us to deliver unparalleled value to our clients. Partner with us to benefit from our in-depth understanding of this innovative technology and gain a competitive edge in bringing your inhalation products to the market faster and more efficiently.

Respimat^® generates a slow moving (gentle) mist comprised of fine (low mass) droplets, enhancing deep lung deposition while minimizing oropharyngeal deposition. Respimat^® is ideal for the delivery of highly potent small molecules and biologics. 

Our strategic partnership with Boehringer Ingelheim means:

• Access to Respimat^®: We enable seamless access to this innovative platform technology for third party companies.
• Unmatched development expertise: Drawing upon our vast experience in SMIs, we guide your program from concept to viable finished product successfully.
• Feasibility to Clinical trial materials: Armed with years of how-how, experience and expanded capabilities, we can support your program from molecule to Phase I/II clinical trials.

Please reach out to bd@kenoxpharma.us, to discuss your pipeline program or learn about our partnering-ready 505(b)(2) assets.